Khullar Dhruv, Andeejani Ahmed M I, Bulsara Ketan R
Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut 06520, USA.
J Neurosurg Pediatr. 2010 Nov;6(5):444-51. doi: 10.3171/2010.8.PEDS10231.
Vein of Galen aneurysmal malformations (VGAMs) continue to account for high morbidity and mortality rates in the pediatric population. Whereas in the past, mortality rates were nearly 100%, recent developments in endovascular embolization and improvements in neonatal care have improved prognoses. It is now possible that some patients can achieve normal neurological development following embolization of the VGAM. Access to the lesion can be gained via transarterial or transvenous routes. In this paper the authors review the pathophysiological characteristics of VGAM and discuss the evolution of treatment options.
A PubMed literature search was performed for vein of Galen malformation treatment options, beginning in the 1970s. A total of 22 papers were reviewed in full, and outcome data for 615 patients from 1983 to 2010 were compiled. Articles were reviewed if they focused primarily on the treatment of VGAM and reported outcomes for at least 5 treated patients.
Of the 265 patient outcomes reported between 1983 and 2000, 200 received endovascular therapy. Of these patients 72% had a favorable outcome, and a 15% mortality rate was found. Microsurgery was found to have an 84.6% mortality rate. Furthermore, 76.7% of untreated patients died. More recently, endovascular embolization has become the mainstay of VGAM treatment. Of the 350 patients assessed between 2001 and 2010, 337 were treated endovascularly, mostly via the transarterial approach. Of these patients, 84.3% were found to have good or fair outcomes, and a 15.7% mortality rate was found. Neonates had the worst clinical outcomes following endovascular treatment, with a 35.6% mortality rate, whereas infants and children had significantly better outcomes, with mortality rates of 6.5% and 3.2%, respectively.
Endovascular embolization has considerably improved outcomes in patients with VGAM. In the past, the prognosis for patients with VGAM was dismal, and successful procedures were considered to be those that partially or completely obliterated the lesion, but did not necessarily improve the patient's symptoms. More recently, with the continued development and improvement of endovascular techniques, many patients are found to be neurologically normal on follow-up, and mortality rates have dropped substantially when compared with microsurgical treatment.
大脑大静脉动脉瘤样畸形(VGAM)在儿科人群中仍具有较高的发病率和死亡率。过去,死亡率几乎为100%,而近年来血管内栓塞技术的发展以及新生儿护理的改善使预后得到了改善。现在,一些患者在VGAM栓塞后有可能实现正常的神经发育。可通过经动脉或经静脉途径到达病变部位。在本文中,作者回顾了VGAM的病理生理特征,并讨论了治疗方案的演变。
对20世纪70年代以来PubMed上关于大脑大静脉畸形治疗方案的文献进行检索。共全面回顾了22篇论文,并汇总了1983年至2010年615例患者的结局数据。如果文章主要关注VGAM的治疗并报告了至少5例接受治疗患者的结局,则对其进行回顾。
在1983年至2000年报告的265例患者结局中,200例接受了血管内治疗。这些患者中72%预后良好,死亡率为15%。显微手术的死亡率为84.6%。此外,76.7%未经治疗的患者死亡。最近,血管内栓塞已成为VGAM治疗的主要方法。在2001年至2010年评估的350例患者中,337例接受了血管内治疗,大多通过经动脉途径。在这些患者中,84.3%预后良好或尚可,死亡率为15.7%。血管内治疗后新生儿的临床结局最差,死亡率为35.6%,而婴儿和儿童的结局明显较好,死亡率分别为6.5%和3.2%。
血管内栓塞显著改善了VGAM患者的结局。过去,VGAM患者的预后很差,成功的手术被认为是那些部分或完全闭塞病变,但不一定能改善患者症状的手术。最近,随着血管内技术的不断发展和改进,许多患者在随访中神经功能正常,与显微手术治疗相比,死亡率大幅下降。